Está usted abandonando el sitio web de Lilly
La liga en la que hizo clic lo llevará a un sitio administrado por un tercero, quien es el único responsable de su contenido. ELI LILLY Y COMPAÑÍA DE MÉXICO S.A. DE C.V. no controla, influye o respalda este sitio, y las opiniones, reclamos o comentarios expresados en este sitio no son responsabilidad de ELI LILLY Y COMPAÑÍA DE MÉXICO S.A. DE C.V. y tampoco la política de privacidad de los sitios web de terceros. Le recomendamos que lea la política de privacidad de cada sitio web que visite. Haga clic en "Continuar" para proceder o "Regresar" para mantenerse en LillyMedical.com/mx
Haga una pregunta para buscar información del producto y recursos médicos de Lilly. Para activar la búsqueda escriba 3 términos.
Por favor no use este campo para reportar eventos adverso o quejas de productos.
Para consultar la información para prescribir completa de Emgality® (Galcanezumab) de clic en el siguiente enlace:
Información para prescribir
La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.
Was galcanezumab associated with palpitations or tachycardia in clinical trials?
The incidences of categorical or sustained increase in pulse at any time post baseline were similar between placebo and galcanezumab, regardless of if they had elevated pulse at baseline.
The information contained in this letter may notcompletely match the current local labeling for GALCANEZUMAB.Please see local labeling approved in your country.
Analysis of Increased Pulse or Heart Rate
The cardiovascular adverse event profile of galcanezumab was evaluated using integrated data from a total of 5 placebo-controlled studies with up to 6 months of galcanezumab exposure (with 573.4 patient-years of exposure).1
Galcanezumab doses were pooled prior to the analysis, as galcanezumab doses were different across studies.1
In these studies, the majority of patients were female (>75%) and Caucasian (>75%), with a mean age of 41 to 42 years.2
Increases in pulse or heart rate were evaluated as
This integrated analysis found that there were no significant differences between galcanezumab and placebo in the frequency of categorical or sustained increases in pulse, regardless of presence of increased pulse at baseline.2 These findings were consistent with, and expand upon, an earlier analysis of cardiovascular safety based on data from 3 placebo-controlled studies.3
Categorical Increases in Pulse Similar to Placebo
Categorical increase in pulse was defined as treatment-emergent high >100 bpm with ≥15 bpm increase from baseline.2
aDefined aselevation >100 bpm with ≥15 bpm increase for 2 consecutive office visits.
bAll galcanezumab doses combined.
Postmarketing Reports of Adverse Events Related to Increased Heart Rate or Palpitations
Postmarketing spontaneous reports in the Eli Lilly and Company spontaneous adverse event database through 27 March 2021 show that
palpitations and heart rate increased were rarely reported, and
heart rate abnormal, heart rate irregular, sinus tachycardia, supraventricular tachycardia, tachycardia, and ventricular tachycardia were very rarely reported.4
Rarely reported is defined as an adverse event that has been reported at an estimated rate of ≥0.01% and <0.1% according to the reporting system information.4 Very rarely reported is defined as an adverse event that has been reported at an estimated rate of <0.01% according to the reporting system information.
Postmarketing data do not necessarily represent the rate of occurrence of an adverse event in a treated population, but they represent a reporting rate of a particular adverse event to the company. Spontaneous reporting of adverse events can be highly variable and is not appropriately controlled clinical information on which to base an assessment of whether a particular drug product is the causal agent of an event.5
Spontaneous reporting has limited use due to
lack of control population
under-reporting or reporting bias, and
missing or incomplete information regarding medical history or concomitant medications.5
3Oakes TM, Kovacs R, Rosen N, et al. Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. Headache. 2020;60(1):110-123. http://dx.doi.org/10.1111/head.13684
4Data on file, Eli Lilly and Company and/or one of its subsidiaries.